Risk of Parkinson's disease following anxiety disorders: A nationwide population-based cohort study

European Journal of Neurology

Volumn 22, Issue 9, 2015, Pages 1280-1287

  Lin, C H ^a   Lin, J W ^a,b   Liu, Y C ^c   Chang, C H ^b,c   Wu, R M ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Anxiety; Depression; Non motor symptoms; Parkinson's disease

Indexed keywords

ANXIOLYTIC AGENT;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; TAIWAN; ANXIETY DISORDERS; SEVERITY OF ILLNESS INDEX;

AGED; ANXIETY DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TAIWAN;

EID: 84939465675     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12740     Document Type: Article

References (23)

1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
2. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Exellence. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245.
3. Dissanayaka NN, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010; 25: 838-845.
4. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.
5. Shen CC, Tsai SJ, Perng CL, Kuo BI, Yang AC. Risk of Parkinson disease after depression: a nationwide population-based study. Neurology 2013; 81: 1538-1544.
6. Fang F, Xu Q, Park Y, et al. Depression and the subsequent risk of Parkinson's disease in the NIH-AARP Diet and Health Study. Mov Disord 2010; 25: 1157-1162.
7. Schuurman AG, van den Akker M, Ensinck KT, et al. Increased risk of Parkinson's disease after depression: a retrospective cohort study. Neurology 2002; 58: 1501-1504.
8. Weisskopf MG, Chen H, Schwarzschild MA, Kawachi I, Ascherio A. Prospective study of phobic anxiety and risk of Parkinson's disease. Mov Disord 2003; 18: 646-651.
9. Bower JH, Grossardt BR, Maraganore DM, et al. Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord 2010; 25: 2105-2113.
10. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000; 15: 669-677.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV, 4th edn. Washington (DC): American Psychiatric Association, 1994.
12. Lin CH, Wu RM, Chang HY, Chiang YT, Lin HH. Preceding pain symptoms and Parkinson's disease: a nationwide population-based cohort study. Eur J Neurol 2013; 20: 1398-1404.
13. Lee YC, Lin CH, Wu RM, Lin JW, Chang CH, Lai MS. Antihypertensive agents and risk of Parkinson's disease: a nationwide cohort study. PLoS One 2014; 9: e98961.
14. Menza MA, Robertson-Hoffman DE, Bonapace AS. Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993; 34: 465-470.
15. Eskow JK, Angoa-Perez M, Kuhn DM, Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment. Neurosci Biobehav Rev 2011; 35: 556-564.
16. Millan MJ. The neurobiology and control of anxious states. Prog Neurobiol 2003; 70: 83-244.
17. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314-1322.
18. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 79-84.
19. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114: 2283-2301.
20. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-319.
21. Dissanayaka NN, White E, O'Sullivan JD, Marsh R, Pachana NA, Byrne GJ. The clinical spectrum of anxiety in Parkinson's disease. Mov Disord 2014; 29: 967-975.
22. Lauterbach EC, Freeman A, Vogel RL. Correlates of generalized anxiety and panic attacks in dystonia and Parkinson disease. Cogn Behav Neurol 2003; 16: 225-233.
23. Jorm AF, Henderson AS, Jacomb PA, et al. Association of a functional polymorphism of the monoamine oxidase A gene promoter with personality and psychiatric symptoms. Psychiatr Genet 2000; 10: 87-90.